Introduction {#s1}
============

Cough is a common symptom associated with upper respiratory tract infections (URTIs).[@R1] In some patients, coughing can persist leading to a syndrome known as postviral or postinfectious cough which is arbitrarily defined as lasting from 3 to 8 weeks, with normal chest radiograph findings.[@R5] [@R6] In some individuals, cough persists even longer, when it is termed a chronic cough.[@R7] While a normal cough is a vital protective reflex preventing aspiration, cough hypersensitivity is the mechanism thought to underlie almost all types of pathological cough.[@R8] This has been demonstrated in URTI.[@R9]

Cough causes a plethora of complications affecting the cardiovascular, gastrointestinal and respiratory systems, with far-reaching psychological, neurological and musculoskeletal effects.[@R6] [@R7] [@R12] While there are many agents on the market to reduce the frequency of cough and aid in the clearance of mucus, a systematic review of over-the-counter preparations failed to recommend any available treatment.[@R13] For example, the use of codeine in respiratory tract infection-associated cough was found to be no more effective than its vehicle,[@R14] and prescription-only medications are often unsuitable for certain groups of individuals.[@R15]

There are three metrics which are used to study cough: cough challenge, cough counting, and subjective end points such as visual analogue scale or quality of life. Cough challenge studies include the use of pro-tussive agents, such as capsaicin and citric acid, which stimulate transient receptor potential (TRP) ion channels to induce cough.[@R16] TRP channels have been popularised as pro-tussive irritant receptors.[@R19] [@R20] However, on account of repeated clinical trial failures in patients with chronic cough using both cough counting and subjective measures, TRPV1 and A1 antagonists as anti-tussives have failed to reach the clinic,[@R21] and an unpublished RCT of inhaled TRPA1 antagonist GRC 17536 (personal communication AHM, 2015). A recent shift of focus now proposes that other channels and receptors, such as P2X receptors, different TRP channels including TRPV4 and TRPM8[@R22] may be responsible for the observed hypersensitivity. It seems unlikely that one single channel, or receptor, is responsible for causing cough hypersensitivity in all participants in cases of postviral and chronic cough.

Research into URTI and cough faces many problems. Research which relies on natural infection of human volunteers is open to a range of uncontrollable variability including incubation time and causative agent (virus genus and serotype). There is also a lack of suitable animal models for studying HRV due to high host specificity of attachment receptors. Major group HRV requires human ICAM-1 receptor[@R25] which is not present in guinea pigs, an animal classically used for studying the cough reflex. However, pathogens such as parainfluenza virus, a rarer cause of the common cold, can infect guinea pigs and produce a postviral cough with a hypersensitive airway response to capsaicin.[@R26] As a result, studying the effects of HRV infection is often carried out in vitro using cell systems. There is a plethora of research into viral induced effects characterised from various respiratory cell lines, leading to a variety of proposed mechanisms for the induction of cough.

Mechanisms {#s2}
==========

Inflammatory mediators {#s2a}
----------------------

HRV infection results in the production a broad profile of inflammatory mediators in the host. The primary inflammatory cytokines reported in HRV infection are interferon (IFN), interleukin (IL) 1, IL-6, IL-8, tumour necrosis factor (TNF) α, granulocyte-macrophage colony-stimulating factor and RANTES. The infection leads to massive upregulation,[@R27] and, consequently, it is often described as a 'cytokine disease'.[@R28] Many symptoms are thought to occur as a result of the effects of inflammatory cytokines releasing of mediators. For example, sore throat may occur as a result of the release of bradykinin.[@R29] The role of these endogeneous mediators is discussed below.

### Bradykinin {#s2a1}

The proinflammatory mediator bradykinin has been suggested as a potent tussive modulator of TRPA1 and TRPV1.[@R30] It is thought to work through phospholipase C (PLC) causing channel phosphorylation and subsequent sensitisation.[@R33] Elevated levels of bradykinin are found in the BAL fluid of patients with inflammatory airway conditions.[@R34] Bradykinin has also been suggested to mediate ACE inhibitor cough[@R32] which affects 15% of patients.[@R35] Bradykinin and PGE2 possess the ability to sensitise the airways to cough stimulus in animal studies which can be effectively abolished on simultaneous application of antagonists to both TRPV1 and TRPA1.[@R36]

### Tachykinins {#s2a2}

Tachykinin peptides, neurokinin A and B, and substance P, are inflammatory neuropeptides, which collectively induce airway hyper-responsiveness, bronchial constriction,[@R37] and increased vascular permeability.[@R38] They also generate substantial mucus secretion[@R39] and the secretion of inflammatory mediators from immune cells.[@R40] It has been suggested that inhibition of tachykinin metabolism by ACE inhibitors is an alternate mechanism for ACE inhibitor cough.[@R43] In HRV infection, tachykinins are released from neurons on TRPV1 activation.[@R40] Unfortunately, the mechanism underlying this activity is currently unknown, and understanding such channel interaction may hold the key to modulating the development of viral and postviral cough. Reduction of degradation of tachykinins by neutral endopeptidases in respiratory viral infection[@R44] are likely to enhance the noxious effects of tachykinins.

Despite its scarcity, substance P in humans has been found to be upregulated, both in nasal epithelium and plasma in chronic cough sufferers.[@R45] The efficacy of substance P, mediated by tachykinin NK-1 receptors,[@R48] is greatly enhanced by prior inflammation. Furthermore, when in excess, it is suggested to lower the threshold of pain perception to noxious stimuli, as demonstrated in several pain-associated disease states.[@R49] [@R50] In guinea pigs, the role of substance P in cough has been extensively investigated. Substance P results in bronchoconstriction but highly variable cough.[@R51] Likewise, in healthy individuals, inhalation of substance P does not cause cough. However, at the same concentration, substance P has the ability to elicit cough in patients with common colds,[@R52] suggesting a hypersensitive state induced by the virus. Additionally, the microvascular leakage of substance P is thought to activate rapidly adapting receptors (RARs)[@R53] which may add to the irritant effect in common cold.

### Calcitonin gene-related peptide {#s2a3}

Evidence for the role of another neuropeptide calcitonin gene-related peptide (CGRP) is mixed. TRP channel (TRPV1) activation induces and controls the release[@R40] [@R54] from C-fibre terminals.[@R55] CGRP has an inhibitory effect in substance P-induced bronchoconstriction,[@R56] and when deficient, causes airway hyper-responsiveness.[@R57] However, an increase in CGRP has been shown in many pain-associated conditions, including migraine and various forms of inflammation.[@R58] [@R59] Chronic cough sufferers have been shown to have increased neuronal levels of CGRP[@R60] [@R61] associated with the enhanced sensitivity to capsaicin.[@R61] These effects appear to be mediated through the cytokines, IL-1β and TNF-α.[@R59] In respiratory syncytial virus (RSV) infection, a rarer cause of URTI in the adult, the development of airway hyper-responsiveness appears to arise through a disruption of CGRP balance.[@R57] [@R62] However, this fails to explain the increased levels found in sufferers of chronic cough. Unlike substance P, CGRP does not directly induce mucus secretion,[@R63] but may indirectly enhance through vasodilation.

The likelihood that substance P, CGRP or neurokinins have some role in cough hypersensitivity is high. Opiates have been shown to be highly effective in a subgroup of patients with cough.[@R15] A possible mode of action is through prejunctional inhibition of peptide release-preventing neurotransmission either centrally, or from afferent nerves adjacent to inflammatory mediator receptors.[@R40]

### Leukotrienes {#s2a4}

Leukotrienes are potent inflammatory mediators of chemotaxis, bronchoconstriction and vascular permeation,[@R64] which are predominately produced by leucocytes, but also by other inflammatory immune cells. Data is scarce on the extent leukotrienes play in HRV infection. However, Seymour *et al*[@R65] identified a significant increase of precursor enzymes within the airways during HRV infection in healthy individuals, which can potentially increase the capacity of leukotriene B~4~ and C~4~ synthesis. Muscarinic receptor involvement has been implicated in the production of leukotriene B~4.~[@R66] In cough-associated eosinophilic inflammation, blockade of leukotriene receptors has been shown to be efficacious.[@R67] However, in a recent study, montelukast, a potent inhibitor of the receptor of leukotriene C~4~ and D~4~, has no effect on cough in the common cold.[@R68]

### Eosinophils {#s2a5}

Eosinophils are important mediators of cough in allergic disease but their role in viral infection is less clear. Eosinophils, if activated, during viral infection release a multitude of molecules including leukotrienes, growth factors, cytokines and major basic protein (MBP).[@R69] MBP binds to as well as alters prejunctional M2 receptor function,[@R70] [@R71] and increases tachykinin release.[@R44] MBP is cytotoxic[@R72] and has been implicated in peripheral nerve remodelling.[@R73] It is found in higher levels in nasal aspirates from children during HRV infection.[@R74] Not only are eosinophils implicated in tachykinin modulation, but during degranulation they also release a potent peroxidase which generates reactive oxygen species (ROS) and reactive nitrogen species. These harmful oxidants are known potent TRPA1 agonists,[@R75] [@R76] which are receptors ascribed to cause cough in humans and guinea pigs.[@R20]

### Muscarinic receptors {#s2a6}

Muscarinic receptors are highly characterised in airway diseases such as asthma and chronic obstructive pulmonary disease with limited evidence of their involvement in respiratory infections. Of the five muscarinic receptors (M1-5), only M1-3 can be found in the respiratory system. M1 is expressed on epithelial cells and submucosal glands of pulmonary veins.[@R77] M3 receptors are heavily expressed on smooth muscle, inflammatory and submucosal cells[@R78] where they mediate bronchoconstriction, mucosal secretion and inflammatory responses.[@R79] M2 receptors predominately regulate cardiac contraction, but can also be localised to respiratory smooth muscle.[@R77] However, the most important role of M2 receptors in the airway is the prejunctional inhibition of acetylcholine release to limit the degree of bronchoconstriction.[@R80] Respiratory viral agents, parainfluenza and RSV, have been shown to cause depletion and dysfunction of M2 receptors,[@R81] thereby exaggerating cholinergic activity. This has been further shown in double-stranded (ds) RNA animal models, independent of inflammation,[@R81] and mediated by IFN release.[@R82] Therefore, viral infection-induced bronchoconstriction, airway hyper-responsiveness and mucus secretion causing cough may be indirectly mediated through M2 receptors.[@R82] M2 dysregulation can be reversed with dexamethasone[@R83] or pilocarpine.[@R80] However, Lowry *et al*[@R84] found anticholinergic bronchodilators to be ineffective against cough in natural URTI. The potent topical corticosteroid, fluticasone, was also ineffective in significantly reducing symptoms of viral URTI and, indeed, significantly increased the bacterial colonisation of the upper airway.[@R85]

Many of the inflammatory mediators discussed above do not directly evoke cough but work synergistically through other pulmonary fibres where the threshold for cough is lowered to provoke the urge to cough. Thus, this change to sensory nerve functionality secondary to these mediators may potentiate and prolong a cough response during and after respiratory viral infection.

Physical damage {#s2b}
---------------

By comparison with other respiratory viruses such as influenza, HRV is renowned for its minimal cytopathic effects.[@R86] It has been suggested that influenza has a higher incidence of cough than that seen with HRV infections.[@R87] Thus, physical disruption of airway integrity may be a factor in a heightened cough response. HRV, or synthetic dsRNA stimuli polyinosinic:polycytidylic acid (poly(I:C)), is able to disrupt airway epithelial cells via disruption of tight junction complexes at apicolateral membranes through dissociation of zona occludin (ZO) 1, occludin, claudin-1, E-cadherin and β-catenin. This leads to a significant reduction in transepithelial resistance[@R88] indicating a loss of epithelial integrity ([figure 1](#BMJRESP2015000118F1){ref-type="fig"}A). Transepithelial resistance can also be decreased through respiratory-localised TRPV4 activation,[@R91] and causes disruption of tight junction complexes leading to increased permeability. But whether these are related or not, are unknown. Whether this viral induced loss of integrity is dependent or independent of an inflammatory response is open to debate.

![(A) Normal healthy airway barrier. In a healthy airway, cells are connected together by tight junction complexes including tight junctions, adherens and gap junctions. Cells are attached to basement membranes by hemidesmosomes and focal contacts. Barrier permeability is minimal and tightly regulated to prevent the excessive release of essential molecules, ions and proteins. The barrier is protective against infection. (B) Human rhinovirus infection in airway epithelial cells. There are two main ways that HRV causes physical disruption of airway barriers, inflammatory-dependent and independent. Both replicating and non-replicating viruses can interfere with airway membrane integrity by disrupting tight junction complexes. This causes a reduction of transepithelial resistance with the potential consequence of contracting a secondary infection. Cytoskeletal remodelling mediated by protein kinase D (PKD) causes an actin reorganisation within infected cells, altering their structure and integrity, further allowing cells to lose their adjoining contacts. Replicating HRV produces a dsRNA intermediate structure which can interact and activate NOD-like receptor X-1 ultimately producing reactive oxygen species. These alone are capable of reducing transepithelial resistance and barrier disruption. Loss of gap junctions and cells leaves gaps within epithelial layers. These allow cytokines, growth factors, immune cells and further viral particles to penetrate deeper layers within the airways, causing dysregulation of cellular signalling. This dysregulation causes further upregulation of various molecules including growth factors, which, in turn, can lead to an increase of receptor expression, such as transient receptor potential channels which have a prolific effect to cause cough (TNF, tumour necrosis factor; IFN, interferon; IL, interleukin).](bmjresp2015000118f01){#BMJRESP2015000118F1}

### Inflammatory independent {#s2b1}

ROS and other oxidants cause barrier disruption and affect permeability in tissues throughout the body[@R92] through cytoskeletal and tight junction interruption. This effect is mirrored in polarised epithelial cells, such as those within the airways.[@R88] [@R93] During infection, HRV causes oxidative stress independent of viral replication or ICAM-1-mediated viral attachment.[@R94] The mechanism is thought to be via a NOD-like receptor X-1 (NLRX-1) interaction with dsRNA causing a translocation of NADPH oxidase-1 (NOX-1) leading to the generation of ROS and oxidants.[@R93] [@R95] By contrast, ROS production is necessary for clearance of viral infections, but requires stringent regulation. Interaction with dsRNA receptor NLRX-1 induces mitochondrial ROS generation.[@R96] [@R97] This is likely a result of mitochondrial antiviral signalling protein interaction with dsRNA,[@R98] an important component of HRV lifecycle.[@R101] ROS are also potent agonists of TRPA1 and TRPV1,[@R75] [@R76] which poses a potential interaction route between HRV and TRP channels.

### Inflammatory dependent {#s2b2}

Other investigators propose that physical disruption is an inflammatory-dependent process caused by TNF-α, IFN-γ, IL-4 and IL-8 which mediate the tight junction dysregulation.[@R102] A cytokine-induced effect may, however, be secondary to signalling pathways aforementioned, and which mechanism predominates may be dependent on specific cell type.

Consequently, varying degrees of barrier disruption and physical damage have the potential to cause a multitude of effects. A loss of integrity to airway barriers enables the transmigration of opportunistic bacteria causing secondary respiratory infection.[@R90] It can also lead to dysregulation of intracellular signalling facilitating the upregulation of growth factors.[@R105] Finally, in exposed animals, an enhanced activation of sensory nerve fibres leads to airway hyper-responsiveness[@R108] and epithelial repair is delayed.[@R109] Thus, there is a cycle of cytokine-induced barrier damage ([figure 1](#BMJRESP2015000118F1){ref-type="fig"}B) leading to epithelial shedding. Airway epithelial lining begins to become permeable to larger molecules[@R88] leading to a cycle of hypersensitivity and further damage.

Physical disruption to airways described above is a well-characterised part of the pathophysiology of lung diseases including asthma and cystic fibrosis, but the role it plays in URTI, such as HRV, has only recently begun to become clear, but may be crucially important in patients with pre-existing respiratory disease.

Mucus {#s2c}
-----

Excessive mucus production and secretion is common in URTI[@R1] [@R110] initiating symptoms such as a cough and sneezing, and thus facilitating transmission of infection.[@R3] [@R111] HRV, in particular, upregulates the transcription of various mucin genes including MUC5AC.[@R112] This pathway is particularly involved in mucus production and release, but this complex process ([figure 2](#BMJRESP2015000118F2){ref-type="fig"}) has yet to be completely characterised. Using nuclear factor (NF) κB and mitogen-activated protein kinase inhibitors, the pathway induced during HRV infection was originally identified. The mechanism is independent of serotype and genotype and is inducible by artificial genomic stimulus using poly(I:C).[@R112] NFκB is upregulated as part of HRV lifecycle,[@R115] [@R116] so it is unsurprising that it plays a pivotal role in the production of symptoms during infection, and is essential for MUC5AC production. HRV is able to induce mucosal cell metaplasia through a novel TLR3-epidermal growth factor receptor (EGFR) coupling and the induction of EGFR ligands,[@R113] including transforming growth factor α. This results in the production and secretion of mucins via MUC5AC promoter regions.[@R112] The process of mucus secretion and tight junction disruption go hand in hand. A loss of epithelial integrity where a dissociation of E-cadherens from adherens tight junction complexes causes the uncoupling of EGFR where it becomes readily activated. However, an excess of EGFR activation promotes goblet metaplasia and, thus, excessive mucus secretion.[@R117] Muscarinic receptors are also involved in mucus secretion, mediated predominately through M3 in cooperation with M1[@R118] and are regulated by M2.[@R119] Since stimulation of muscarinic receptors transactivate EGFR to stimulate goblet cell mucus secretion,[@R120] [@R121] it is possible that HRV possesses the ability to interact with muscarinic receptors to cause this process. The implications of this are far-reaching as not only may it begin to explain the aetiology of a viral mucosal cough but also chronic mucus secretion such as occurs in chronic bronchitis.

![Sterile-α-motif-pointed domain ETS-factor (SPDEF) and epidermal growth factor receptor (EGFR) regulation of mucus production and goblet cell metaplasia within the airways during upper respiratory tract infection (URTI). Reactive oxygen species (ROS)-induced uncoupling of EGFR permits its translocation to the apical membrane of cells which readily allows its activation. Excessive activation of EGFR promotes various cellular processes including goblet cell metaplasia and upregulation of mucus-associated genes including MUC5AC. Simultaneously, SPDEF is activated to dampen the inflammatory response mounted against the rhinovirus infection through blockade of TLR signal transduction. SPDEF also functions as a transcription modulator and causes upregulation of MUC5AC. Ultimately, increased MUC5AC and goblet metaplasia results in the hyperproduction of mucus, characteristic of rhinovirus infection.](bmjresp2015000118f02){#BMJRESP2015000118F2}

A counter-regulatory mechanism to HRV-induced TLR-EGFR coupling is by induction of the transcription factor sterile-α-motif-pointed domain ETS-factor (SPDEF). SPDEF inhibits TLR signalling and type I IFN release to dampen the proinflammatory response induced by HRV.[@R122] SPDEF is a transcriptional modulator with a wide variety of roles including endocrine and androgen interaction,[@R123] [@R124] however, recently this transcription modulator was found to regulate goblet cell metaplasia[@R123] [@R125] and upregulate genes associated with mucus production,[@R126] including MUC5AC.[@R125] It has been suggested that SPDEF initiates recovery and protects against excessive inflammatory damage during metaplasia. Dysregulation of this pathway may permit the cycle of cough and damage to persist, exposing basal membranes and nerve fibres, allowing HRV-induced physical damage and mucus overproduction to act synergistically.

Many patients have a dry or non-productive cough, and thus, an important cofactor mucus production alone is insufficient to explain coughing in URTI. Excessive mucus may exacerbate cough by several mechanisms including a stretch response and altered tonicity. Present within mucus are nucleosides and nucleotides, namely ATP and its breakdown products.[@R127] ATP release occurs through cellular swelling mediated via pannexin-1[@R128] and subsequent ATP-induced ATP release.[@R131] Purinergic receptors are increasingly thought to be important mediators of cough hypersensitivity, and are discussed further in the section on neuronal mechanisms. In terms of mucus secretion, P2Y receptors enhance intracellular calcium concentrations and subsequent ciliary beat frequency.[@R132] [@R133] P2X7 is known to colocalise and interact with Pannexin-1.[@R134] As part of the pore-forming complex of P2X7 receptor, pannexin-1 forms a death complex through extended pore dilation and increased permeability.[@R135] [@R137] [@R138]

In recent years, an increasing number of studies have begun to implicate TRPV4 in mucociliary clearance and airway defence, as it is essential for epithelial barrier function,[@R91] and is highly expressed in ciliated tracheal cells.[@R139] As well as arachidonic acid metabolites,[@R142] TRPV4 can be activated through mechanical and osmotic stimulus,[@R143] such as viscous and hypotonic mucus, to induce and regulate calcium release.[@R144] Not only does this activate the channel but it also regulates ciliary beat frequency[@R141] and mucus secretion, mediated by aquaporin 5.[@R145]

Neuronal modulation {#s2d}
-------------------

Cough is clearly a neuronal reflex, so the hypothesis that neuronal modulation underlies the pathogenesis of viral cough is the most convincing. However, at present, there is no single comprehensive mechanism which explains cough induced by HRV or indeed any other respiratory pathogen. Theories include a cooperative role of pulmonary oxidative stress in vagal sensory nerves between TRPV1, TRPA1 and P2X receptors.[@R146] Direct viral damage to mitochondria leading to ROS production may modulate or influence cough.

During URTI sensitivity to capsaicin, citric acid and histamine are transiently increased with a reduction in cough threshold,[@R10] [@R11] [@R147] [@R148] without concurrent hyper-responsiveness to methacholine.[@R11] This suggests that HRV-induced cough is independent of bronchial smooth-muscle tone. This was originally proposed to occur through the sensitisation of RARs,[@R149] but despite convincing evidence, RARs do not express TRPV1 receptors and are insensitive to chemical stimuli.[@R150] As such, they are no longer proposed to be the primary fibre involved in the cough reflex,[@R23] but may have a synergistic interaction with C-fibres.[@R151] As a result of these findings, capsaicin-sensitive nerves are not the same nerves known to initiate pathological cough, despite the clear observation that inhaled aerosolised capsaicin produces a cough.[@R18] These observed differences may be explained by phenotypic changes to nerve fibres induced during inflammation.[@R152]

Phenotypic changes imply altered gene expression and differentiation. In the guinea pig, low threshold mechanosensitive sensory nerves express TrkA,[@R153] and application of other growth factors induce the functional expression of TRPV1 and TRPA1 de novo*.*[@R152] In vivo research in the rat and guinea pig models have found inflammatory states through increased nerve growth factor (NGF) levels causing a phenotypic change of A-delta fibres. They now resemble C-fibres as shown by the coexpression of substance P and NGF.[@R154] [@R155] NGF is transported to sensory neurons via DRG and is able to alter transcription of various proteins and peptides.[@R156] Further research into the effect of NGF on TRPV1 by Chuang *et al*[@R33] and Ganju *et al*[@R157] found that NGF activates the PLC pathway. TRPV1 associates with phosphatidylinositol 4,5-bisphosphate (PIP~2~) in its resting state, but PLC activation causes the hydrolysis of PIP~2~ to release TRPV1 from constitutive inhibition, thus increasing the opening probability of TRPV1.

Similarly, HRV infection in the human has been shown to cause the upregulation of a number of growth factors.[@R105] Specifically, HRV can induce the upregulation of NGF[@R158] and inhalation of aerosolised NGF can enhance cough in the guinea pig citric acid-induced cough model through TRPV1 and TrkA (NGF receptor) activation.[@R159] [@R160] Despite the differences between human and guinea pig airway innervation, it is these modifications in expression that may lead to a phenotypic change during URTI.

Interest into the role of TRPV4 and P2X receptors in cough has been growing exponentially. A recent abstract publication showed that the application of a TRPV4 agonist facilitated the subsequent activation of P2X3 receptor through sensitisation of airway sensory nerves.[@R161] This is not the first time TRPV4 and P2X3 receptors have been hypothesised to play a cooperative role in pathophysiology.[@R162] It has become apparent that there is significant overlap between TRP channel and purinergic receptor functionality, which have given rise to the persuasive theory that TRPV4 and purinergic receptors play a cooperative role in pathological cough. ATP, which has been shown to enhance cough reflex sensitivity[@R24] in response to citric acid and histamine challenge,[@R163] potentiates through P2X2/X3-mediated bronchoconstriction.[@R164] [@R165] A successful clinical trial using AF-219, a P2X3 antagonist, reduced the incidence of coughing in patients with chronic cough by 75%,[@R166] provides more convincing evidence that cough sensitivity may be strongly upregulated by the P2X pathway.

Neurogenic inflammation from afferent sensory neurons[@R167] is mediated mostly, but not exclusively, by neuropeptides CGRP, neurokinins and substance P. When present, it is thought to be a protective reflex, facilitating healing and modulation of local immunity. Unfortunately, there is wide interspecies and, in man, intersubject variability in afferent sensory innervation making interpretation of experimental findings difficult to translate into clinical relevance. However, neurogenic inflammation is well characterised in several diseases, including migraine,[@R168] and more controversially in asthma[@R169] and rhinitis, the latter of which is common in URTI,[@R170] where it likely amplifies maladaptive responses. Neurogenic inflammation is essential for sensory neurons to prime and respond to noxious stimuli quickly. Consequently, afferent neurons are abundant in TRP channels, P2X, PAMPs and DAMP receptors. Only a limited set of TLRs, 3, 4, 7 and 9, are present within nociceptive neurons,[@R171] therefore, not all pathogens are capable of directly causing neurogenic inflammation. Stimulation of these TLRs induce an inward depolarisation to elicit neuronal sensitisation to pain stimuli.[@R171] A recent interesting finding identified TLR 7 stimulation leading to an itch-specific sensory pathway,[@R173] through intracellular microRNA let-7b. This, in turn, induces a rapid inward current in neurons, coexpressing TLR7 and TRPA1 to generate pain.[@R174] [@R175] Extracellular ATP is a crucial damage-associated molecular pattern molecule ligand which is released during damage and injury. In nociceptive neurons, P2X3 receptors are key to ATP recognition and pain production.[@R176] Purinergic receptor P2Y2 is also responsive to ATP, and is capable of TRPV1 sensitisation and activation in the absence of TRPV1 stimuli,[@R177] a similar sensation previously ascribed to TRPV4 through HRV-induced mucus overproduction. Cytokines, namely IL-1β and TNF-α, produced as a result of infection cause TRP channel sensitisation and activation through membrane phosphorylation.[@R178] [@R179] The resultant effect means that TRP channels respond to innocuous stimuli as noxious stimuli causing allodynia and, perhaps, allotussia.

There is a surprising degree of overlap in the physiological location and functionality of thermo-TRP channels and P2X receptors. TRPA1 is reported to possess mechanotransductive properties likely attributable to their distinct characteristic ankyrin repeats[@R180] in the inner ear to permit hearing,[@R181] although this is disputed by other groups.[@R182] However, despite this, an interesting notable finding was the identification of P2X receptors, also within the inner ear, and that their initial action potential firing is necessary for the maturation of hearing.[@R183] Likewise in the bladder, TRPV1, TRPV2, TRPV4, TRPA1 and TRPM8 all have mechanosensory roles[@R184] to interpret stretch and pain perception,[@R185] whilest P2X2 and P2X3 play a major role in distension sensation to excite a micturition reflex.[@R186] Most relevant to cough is their influence on pain. TRPA1 and TRPV1 are well characterised to elicit pain signals in response to noxious stimuli[@R187] [@R188] P2X2, P2X3, P2X4 and P2X7 having all been identified to play some form of role in various types of pain.[@R189] Most importantly in neuropathic pain where some pharmacological agents which have shown promising results in clinical trials.[@R193] Relevant to these observations is that P2X2 and P2X3 receptors expressed on afferent neurons are home to the classic pain sensation channel TRPV1.[@R194]

The role of TRP channels in HRV-induced cough has recently been explained in a first-of-its-kind study by Abdullah *et al*.[@R195] A novel infection site of HRV was identified in neuronal cell lines with concomitant upregulation of expressed TRP channels TRPA1, TRPV1 and TRPM8 found on airway sensory nerves. HRV infection accounts for up to 50% of exacerbations in asthmatics,[@R196] and both asthmatic[@R197] and chronic cough sufferers[@R198] [@R199] have higher levels of TRP channels expressed in their airways. This finding adds to the mounting evidence that TRP channels play a major role in cough during HRV infections, but requires further investigation to definitively confirm this.

Summary {#s3}
=======

A postviral cough is generally unresponsive to conventional pharmacological intervention, but has shown limited responsiveness to the anticholinergic drug, tiotropium,[@R200] which leaves a major hole in our therapeutic armamentarium. Currently, treatment merely consists of dampening the inflammatory response with the use of antiinflammatories (such as naproxen),[@R201] and cough suppressants (codeine-containing products and dextromethorphan),[@R15] in the hope of reducing the frequency, severity and transmission of cough. Opiates, although commonly prescribed, are not generally recommended for viral cough due to their poor efficacy and significant adverse effect profile.[@R15]

The multiple mechanisms described above provide a confusing and inter-related 'soup' of potential therapeutic targets, dissecting which, are the key players involved in this common affliction that will be challenging. We suggest that modulation of the afferent neuronal hypersensitivity will provide the most fruitful target in what is essentially a benign and self-limiting disease. Other strategies, such as systemic immune modulation, run the risk of generating unforeseen off-target effects. The rewards for understanding the mechanism of viral-induced cough will have enormous impact on human morbidity.
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